While Elon Musk’s Neuralink continues to dominate headlines with its high-profile brain implant trials, a quieter — and potentially larger — revolution is unfolding in China. Chinese BCI startups are moving from laboratory research to commercialization at an unprecedented pace, fueled by strong policy support, massive government funding, and a healthcare system that can accelerate approvals in ways the US cannot match. ## The Numbers: From $530M to $120B China’s BCI market was expected to grow to more than $530 million (3.8 billion yuan) in 2025, up from 3.2 billion yuan in 2024. Industry projections now put the market at over 120 billion yuan ($16.5 billion) by 2040. This isn’t speculative future-tech — this is healthcare-grade deployment happening now. ## The Four Factors Behind China’s BCI Acceleration According to Phoenix Peng, co-founder of NeuroXess (implantable BCIs) and founder of Gestala (noninvasive ultrasound BCIs), China’s rapid progress comes down to four key factors: 1. Policy Alignment and Government Funding In August 2025, China’s industry ministry released a national BCI roadmap targeting major technical milestones by 2027, common industry standards by 2029, and a full supply chain by 2030. At the December 2025 Shenzhen BCI & Human-Computer Interaction Expo, China announced an 11.6 billion yuan ($165 million) brain science fund. Provinces including Sichuan, Hubei, and Zhejiang have already set medical service pricing for BCI procedures, speeding inclusion in the national health insurance system. 2. Clinical Resources and Regulatory Speed China’s massive patient pools and lower research costs accelerate trials. Once the state approves a BCI device, national health insurance enables rapid commercialization. This contrasts sharply with the US, where FDA approval is only the beginning — private insurers must each individually decide coverage. Chinese researchers have now completed the country’s first fully implanted, wireless BCI trial — only the second globally after Neuralink. 3. Manufacturing Infrastructure China’s mature industrial base across semiconductors, AI, and medical hardware supports fast R&D and prototyping. The same supply chains that produce smartphones and EVs are now being repurposed for neurotechnology. 4. Investment Surge State-led funds and private capital are flowing into the sector. Notable deals include StairMed Technology raising $48 million in Series B, and BrainCo raising $287 million before filing for a Hong Kong IPO. HSG (formerly Sequoia China) has invested in Zhiran Medical, focused on improving long-term implant performance. ## The Two Paths: Invasive vs Noninvasive China’s BCI ecosystem is pursuing both major approaches: - Invasive BCIs: Companies like NeuroXess and NeuralMatrix implant flexible electrodes directly into the brain for precise neuron-level signals. Over 50 flexible implantable BCI clinical trials were completed by mid-2025. - Noninvasive BCIs: Companies like Gestala and BrainCo use ultrasound, EEG, and other techniques that trade some precision for safety and ease of adoption. Ultrasound BCIs from companies like OpenAI-backed Merge Labs and Gestala are targeting high-precedence conditions such as chronic pain, stroke, and depression. Early trials have shown a single session can reduce pain scores by 50%, with effects lasting one to two weeks. ## Key Players in China’s BCI Race The most active Chinese BCI companies include: - NeuroXess — invasive flexible implants - Neuracle — neural signal recording - NeuralMatrix — brain-machine interfaces - BrainCo — noninvasive BCIs and bionic limbs (IPO filed) - StairMed — raised $48M Series B - Gestala — ultrasound-based BCI (launched January 2026) - Zhiran Medical — long-term implant performance (HSG-backed) ## The AI-BCI Convergence “I have always maintained that neuroscience and AI are two sides of the same coin,” said Peng. “They are destined for deep integration, realizing direct high-bandwidth connections between the human brain and AI. BCI will serve as the ultimate bridge between carbon-based and silicon-based intelligence.” This vision — brain-AI symbiosis — represents the long-term play. But over the next three to five years, BCI use will likely stay concentrated in healthcare, with the market reaching multibillion-dollar scale as insurance coverage expands. ## Key Takeaways - Policy-Driven Acceleration: China’s government has committed $165M in direct funding and integrated BCIs into provincial health insurance systems, creating a commercialization pathway that doesn’t exist in the US. - Clinical Volume Advantage: 50+ flexible implantable BCI trials completed by mid-2025, with China’s first fully wireless implanted BCI now operational — making it only the second country (after the US) to achieve this. - Market Scale: $530M in 2025 growing to projected $120B by 2040 — a 200x expansion in 15 years. - Dual-Track Strategy: China is pursuing both invasive (Neuralink-style) and noninvasive (ultrasound/EEG) approaches simultaneously, hedging bets and serving different market segments. - The AI Integration Story: Chinese founders are explicitly framing BCI as the “bridge between carbon and silicon” — positioning neurotechnology as essential infrastructure for the coming AGI era, not just a medical device. - Investment Heat: BrainCo’s $287M raise and IPO filing, plus StairMed’s $48M Series B, signal serious capital backing. The sector is moving from research to growth stage. The brain-computer interface race is no longer a US monopoly. China’s integrated policy, manufacturing, and healthcare ecosystem may prove to be a decisive advantage in scaling this technology from experimental trials to mass-market deployment.